Satoshi Kitai
Overview
Explore the profile of Satoshi Kitai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
990
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, et al.
Dig Dis
. 2016 Oct;
34(6):671-678.
PMID: 27750236
Background: The standard treatment option that is available for patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) is transarterial chemoembolization (TACE). However, the condition of the...
2.
Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, et al.
Liver Cancer
. 2016 Aug;
5(3):175-89.
PMID: 27493893
Background & Aims: Hepatocellular carcinoma (HCC) with decompensated liver cirrhosis (LC) is a life-threatening condition, which is amenable to liver transplantation (LT) as the standard first-line treatment. However, the application...
3.
Ueshima K, Kudo M, Tanaka M, Kumada T, Chung H, Hagiwara S, et al.
Liver Cancer
. 2016 Jan;
4(4):263-73.
PMID: 26734580
We conducted a phase I/II study in patients with advanced hepatocellular carcinoma (HCC) to determine the recommended dose, as well as the safety and efficacy, of combination therapy of sorafenib...
4.
Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, et al.
Liver Cancer
. 2016 Jan;
4(4):253-62.
PMID: 26734579
Background And Aims: Patients with intermediate-stage hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE) are considered to be candidates for sorafenib. The aim of this study was to evaluate...
5.
Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, et al.
Oncology
. 2015 Nov;
89 Suppl 2:47-52.
PMID: 26584036
Introduction: Barcelona Clinic Liver Cancer (BCLC) stage B, an intermediate stage, includes various conditions of hepatocellular carcinoma (HCC). This heterogeneity of the patients with intermediate-stage HCC makes it difficult to...
6.
Minami Y, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, et al.
Oncology
. 2015 Nov;
89 Suppl 2:27-32.
PMID: 26584033
Objective: To investigate whether balloon-occluded transcatheter arterial chemoembolization (b-TACE) can produce a more dense accumulation of iodized oil in various stages of hepatocellular carcinoma (HCC), from single to uncountable, to...
7.
Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, et al.
Oncology
. 2015 Nov;
89 Suppl 2:4-10.
PMID: 26584030
Objective: Transarterial chemoembolization (TACE) is recommended as a first-line therapy for hepatocellular carcinoma (HCC) patients ineligible for curative therapy and without portal invasion. The Assessment for Retreatment with TACE (ART)...
8.
Nishida N, Iwanishi M, Minami T, Chishina H, Arizumi T, Takita M, et al.
Dig Dis
. 2015 Oct;
33(6):745-50.
PMID: 26489010
Objectives: Several studies revealed that the proportion of hepatocellular carcinoma (HCC) without hepatitis virus infection (NBNC-HCC) is increasing. On the other hand, epigenetic alterations are reportedly responsible for HCC development....
9.
Arizumi T, Ueshima K, Iwanishi M, Chishina H, Kono M, Takita M, et al.
Dig Dis
. 2015 Oct;
33(6):728-34.
PMID: 26488730
Objectives: Sorafenib has become a standard therapy for advanced hepatocellular carcinoma following the demonstration of significant increase in progression-free survival as well as overall survival (OS) in the 2-phase III...
10.
Nishida N, Iwanishi M, Minami T, Chishina H, Arizumi T, Takita M, et al.
Dig Dis
. 2015 Oct;
33(6):708-14.
PMID: 26488400
Objectives: Triple therapy using peg-interferon, ribavirin and simeprevir (PEG-IFN/RBV/SMV) has reportedly resulted in high-sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC), especially in naïve cases and...